Alexandra Soldatou

Dr. Alexandra Soldatou

2nd Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias, Goudi, 11527 Athens, Greece
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2016 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
KKKyriaki A. Karavanaki
Kyriaki A. Karavanaki
ASAlexandra Soldatou
Alexandra Soldatou
AKAthina Maria Koufadaki
Athina Maria Koufadaki
CTCharalampos Tsentidis
Charalampos Tsentidis
FHFotis A. Haliotis
Fotis A. Haliotis
CSConstantinos J. Stefanidis
Constantinos J. Stefanidis

13 May 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
DKDimitra Kallinikou
Dimitra Kallinikou
ASAlexandra Soldatou
Alexandra Soldatou
CTCharalambos Tsentidis
Charalambos Tsentidis
MLMaria Louraki
Maria Louraki
CKChristina Kanaka‐Gantenbein
Christina Kanaka‐Gantenbein
KKKyriaki Karavanaki
Kyriaki Karavanaki

3 May 2014 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
AGAnastasia Garoufi
Anastasia Garoufi
SVStyliani Vorre
Styliani Vorre
ASAlexandra Soldatou
Alexandra Soldatou
CTCharalampos Tsentidis
Charalampos Tsentidis
LKLydia Kossiva
Lydia Kossiva
DGDimitrios Gourgiotis
Dimitrios Gourgiotis
Small dense low density lipoprotein-cholesterol (sdLDL-C) molecules are more atherogenic compared with large buoyant ones. Phytosterols-enriched diets are effective in decreasing total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) concentrations in hyperlipidemic children without significant adverse effects. Limited data on the impact of such a diet on sdLDL-C levels is available in adults while there are no reports concerning children. The purpose of this study is to prospectively evaluate the effect of the daily consumption of 2 g of plant sterols on sdLDL-C levels in children with hypercholesterolemia.

17 July 2023 in Children
Verified
Journal Article
Open access
PDF file
DHDESPINA HEROUVI
DESPINA HEROUVI
GPGeorge Paltoglou
George Paltoglou
ASAlexandra Soldatou
Alexandra Soldatou
CKChristina Kalpia
Christina Kalpia
SKSpyridon Evangelos Karanasios
Spyridon Evangelos Karanasios
KKKyriaki Athina Karavanaki
Kyriaki Athina Karavanaki
Obesity is a multifactorial chronic impairment that further decreases quality of life and life expectancy. Worldwide, childhood obesity has become a pandemic health issue causing several comorbidities that frequently present already in childhood, including cardiovascular (hypertension, dyslipidemia), metabolic (Type 2 diabetes mellitus, fatty liver disease, metabolic syndrome), respiratory, gastrointestinal and musculoskeletal disorders. In addition, obese children frequently experience stress and psychosocial symptoms, including mood disorders, anxiety, prejudice and low self-esteem. Given that cardiovascular risk factors and pediatric obesity have the tendency to pertain into adulthood, obesity management, including weight control and physical activity, should start before the late teens and certainly before the first signs of atherosclerosis can be detected. This review aims to concisely present options for childhood obesity management, including lifestyle modification strategies and pharmacological treatment, as well as the respective treatment indications for the general practitioner.

18 May 2018 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
BPBilio Paouri
Bilio Paouri
ASAlexandra Soldatou
Alexandra Soldatou
EPEftihia Petrakou
Eftihia Petrakou
MTMaria Theodosaki
Maria Theodosaki
CTCharalampos Tsentidis
Charalampos Tsentidis
EGEugenios Goussetis
Eugenios Goussetis

1 January 2013 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
LKLydia Kossiva
Lydia Kossiva
ASAlexandra Soldatou
Alexandra Soldatou
DGDimitrios Gourgiotis
Dimitrios Gourgiotis
KSKonstantinos Stamoulis
Konstantinos Stamoulis
CTCharalampos Tsentidis
Charalampos Tsentidis
Hepcidin is classified as a type II acute phase protein; its production is a component of the innate immune response to infections.